川宁生物
(301301)
| 流通市值：63.88亿 | | | 总市值：230.59亿 |
| 流通股本：6.18亿 | | | 总股本：22.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,435,984,280.4 | 2,348,584,042.47 | 1,296,949,550.16 | 5,758,307,742.65 |
| 营业收入 | 3,435,984,280.4 | 2,348,584,042.47 | 1,296,949,550.16 | 5,758,307,742.65 |
| 二、营业总成本 | 2,650,557,983.64 | 1,753,026,754.01 | 947,594,552.57 | 4,059,755,762.3 |
| 营业成本 | 2,308,976,930 | 1,506,264,144.12 | 812,756,130.56 | 3,663,092,094.72 |
| 税金及附加 | 55,640,708.47 | 39,636,795.07 | 21,599,522.63 | 79,702,258.62 |
| 销售费用 | 19,142,753 | 13,519,060.76 | 7,951,719.02 | 25,535,803.1 |
| 管理费用 | 157,758,113.09 | 110,134,758.43 | 57,530,117.63 | 165,339,123.19 |
| 研发费用 | 83,635,566.63 | 67,633,713.96 | 40,094,047.08 | 77,730,007.1 |
| 财务费用 | 25,403,912.45 | 15,838,281.67 | 7,663,015.65 | 48,356,475.57 |
| 其中:利息费用 | 30,820,819.32 | 21,408,498.95 | 10,822,194.48 | 61,910,260.03 |
| 其中:利息收入 | 3,904,504.68 | 3,007,428.48 | 1,710,866 | 7,380,663.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -226,400 | 4,354.45 | 0 | 31,500 |
| 加:投资收益 | -2,025,204.33 | -702,783.68 | -160,907.91 | -9,195,188.62 |
| 资产处置收益 | 352,143.38 | 352,143.38 | - | - |
| 资产减值损失(新) | -23,132,579.66 | -23,132,579.66 | - | -17,074,166.48 |
| 信用减值损失(新) | -8,114,710.29 | -6,103,689.11 | -1,900,149.05 | 6,686,177.89 |
| 其他收益 | 15,656,604.43 | 9,456,512.72 | 6,037,843.69 | 8,762,622.54 |
| 四、营业利润 | 767,936,150.29 | 575,431,246.56 | 353,331,784.32 | 1,687,762,925.68 |
| 加:营业外收入 | 179,734.41 | 169,664.56 | 4,442.5 | 1,102,808.37 |
| 减:营业外支出 | 16,341,088.27 | 16,097,717.58 | 3,333,480.91 | 13,773,894.74 |
| 五、利润总额 | 751,774,796.43 | 559,503,193.54 | 350,002,745.91 | 1,675,091,839.31 |
| 减:所得税费用 | 140,870,849.82 | 104,927,532.53 | 61,796,149.39 | 274,741,619.34 |
| 六、净利润 | 610,903,946.61 | 454,575,661.01 | 288,206,596.52 | 1,400,350,219.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 610,903,946.61 | 454,575,661.01 | 288,206,596.52 | 1,400,350,219.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 611,393,152.05 | 454,858,252.1 | 288,218,532.72 | 1,400,324,129.94 |
| 少数股东损益 | -489,205.44 | -282,591.09 | -11,936.2 | 26,090.03 |
| 扣除非经常损益后的净利润 | 607,985,214.8 | 456,441,763.18 | 283,038,873.72 | 1,398,418,964.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.2 | 0.13 | 0.63 |
| (二)稀释每股收益 | 0.27 | 0.2 | 0.13 | 0.63 |
| 八、其他综合收益 | - | - | - | -99,338.34 |
| 归属于母公司股东的其他综合收益 | - | - | - | -99,338.34 |
| 九、综合收益总额 | 610,903,946.61 | 454,575,661.01 | 288,206,596.52 | 1,400,250,881.63 |
| 归属于母公司股东的综合收益总额 | 611,393,152.05 | 454,858,252.1 | 288,218,532.72 | 1,400,224,791.6 |
| 归属于少数股东的综合收益总额 | -489,205.44 | -282,591.09 | -11,936.2 | 26,090.03 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-29 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |